All In Biotech

Investigational drug · Phase 3

IMNN-001

Also called: IL-12 Plasmid with PEG-PEI-Cholesterol Lipopolymer, GEN-1

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

4

Any phase or sponsor naming "IMNN-001"

First trial start

2018

Sep 5, 2018

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "IMNN-001", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Fallopian Tube Cancer
  • Epithelial Ovarian Cancer
  • Ovarian Cancer
  • Primary Peritoneal Cancer
  • Primary Peritoneal Carcinoma

Approved drugs for the same conditions: Ovarian cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "IMNN-001" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 102 on PubMed

Also in development for Fallopian Tube Cancer

  • FianlimabREGN3767Phase 311 trials

    Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma

  • R-DXdDS 6000a, MK-5909Phase 310 trials

    Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer

  • UtidelonePhase 38 trials

    Beijing Biostar Pharmaceuticals Co., Ltd. · Ovarian Cancer, HER2-negative Breast Cancer Patients With Brain Metastases, Gastric or Gastroesophageal Junction Adenocarcinoma

  • ONC-392Gotistobart, BNT316Phase 35 trials

    OncoC4, Inc. · Non Small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumor

  • H2 receptor antagonistPhase 34 trials

    Merck & Co. · Lung Neoplasm Malignant, Esophageal Squamous Cell Carcinoma, Ovarian Cancer

  • ZN-c3azenosertibPhase 34 trials

    K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Ovarian Cancer, High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer, Uterine Serous Carcinoma

  • H1 receptor antagonistPhase 33 trials

    Merck & Co. · Lung Neoplasm Malignant, Ovarian Cancer, Fallopian Tube Cancer

  • HS-20089Phase 33 trials

    Hansoh BioMedical R&D Company · Ovarian Cancer, Platinum-sensitive Recurrent Ovarian Cancer, Fallopian Tube Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.